BRPI0822292A2 - Fármaco-alvo eficaz para o tratamento de tuberculose - Google Patents

Fármaco-alvo eficaz para o tratamento de tuberculose

Info

Publication number
BRPI0822292A2
BRPI0822292A2 BRPI0822292-4A BRPI0822292A BRPI0822292A2 BR PI0822292 A2 BRPI0822292 A2 BR PI0822292A2 BR PI0822292 A BRPI0822292 A BR PI0822292A BR PI0822292 A2 BRPI0822292 A2 BR PI0822292A2
Authority
BR
Brazil
Prior art keywords
tuberculosis
treatment
target drug
effective target
drug
Prior art date
Application number
BRPI0822292-4A
Other languages
English (en)
Inventor
Giovanna Riccardi
Giulia Manina
Maria Rosalia Pasca
Original Assignee
Sentinel Ch S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentinel Ch S P A filed Critical Sentinel Ch S P A
Publication of BRPI0822292A2 publication Critical patent/BRPI0822292A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0822292-4A 2008-02-13 2008-02-13 Fármaco-alvo eficaz para o tratamento de tuberculose BRPI0822292A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/001088 WO2009100731A1 (en) 2008-02-13 2008-02-13 An effective new drug target for the treatment of tuberculosis

Publications (1)

Publication Number Publication Date
BRPI0822292A2 true BRPI0822292A2 (pt) 2015-06-30

Family

ID=39401000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822292-4A BRPI0822292A2 (pt) 2008-02-13 2008-02-13 Fármaco-alvo eficaz para o tratamento de tuberculose

Country Status (7)

Country Link
US (1) US9128088B2 (pt)
EP (1) EP2240777B1 (pt)
CN (1) CN101971031A (pt)
BR (1) BRPI0822292A2 (pt)
ES (1) ES2434116T3 (pt)
RU (1) RU2474621C2 (pt)
WO (1) WO2009100731A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103122364A (zh) * 2011-11-21 2013-05-29 华中农业大学 抗结核抑制剂筛选的靶标基因Rv2498c及应用
CN106511366B (zh) * 2016-11-24 2019-08-13 重庆本贝得生物工程技术研究院有限公司 治疗缺血性脑中风的药物及其制备方法与用途
CN108611358A (zh) * 2018-04-10 2018-10-02 佛山科学技术学院 一种通过合成生物学制备异烟肼烟酰胺腺嘌呤二核苷酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522247A (en) 1967-11-07 1970-07-28 Pfizer & Co C 2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators
US6268201B1 (en) 1998-10-23 2001-07-31 Albert Einstein College Of Medicine Of Yeshiva University IniB, iniA and iniC genes of mycobacteria and methods of use
AU1657501A (en) * 1999-11-12 2001-06-06 Regents Of The University Of California, The Determining the functions and interactions of proteins by comparative analysis
US6905822B2 (en) 2000-06-26 2005-06-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of diagnosing multidrug resistant tuberculosis
AU2003289176A1 (en) * 2002-12-05 2004-07-29 Takeda Pharmaceutical Company Limited 1,3-benzothiazinone derivatives, process for producing the same and use thereof
WO2005092872A1 (en) 2004-03-26 2005-10-06 Arpida A/S Peptide deformylase inhibitors
JP5068813B2 (ja) 2006-05-24 2012-11-07 ライブニッツ インスティトゥート フォー ナチュラル プロダクト リサーチ アンド インフェクション バイオロジー エー．ファウ． ハンス−クネル−インスティトゥート（ハーカーイー） 新規なベンゾチアジノン誘導体、及び抗菌剤としてのその使用

Also Published As

Publication number Publication date
EP2240777B1 (en) 2013-08-07
CN101971031A (zh) 2011-02-09
EP2240777A1 (en) 2010-10-20
RU2474621C2 (ru) 2013-02-10
US20110262361A1 (en) 2011-10-27
WO2009100731A1 (en) 2009-08-20
US9128088B2 (en) 2015-09-08
ES2434116T3 (es) 2013-12-13
RU2010137820A (ru) 2012-03-20

Similar Documents

Publication Publication Date Title
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
BR112013010157A2 (pt) inibidores do ibat para o tratamento de doenças do fígado
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
PT2504005E (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0813670A2 (pt) Compostos para tratamento
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa)
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements